Tiny REPLY DR and OVATIO DR Bring Huge Improvements

SORIN was founded 50 years ago as a nuclear plant research company. Evolving into the largest cardiovascular company in Europe brought changes to the company's name and identity. Wanting to encapsulate this evolution, the new Sorin Group's logo displays these recent changes and developments: their aptitude for innovation, their vision for the future, and their force and vitality. The company's motto, "At the Heart of Medical Technology", concisely expresses not only what they do, but also depicts the efforts and commitment that is put into their work. The Sorin Group's hard work translates into increased chances for a better quality of life and longer life expectancy for patients all over the world.

Sorin's REPLY Pacemaker is just slightly larger than a quarter, but has a longevity of nine years.

In order to remain a strong competitor in the innovative and diverse medical technology industry, Sorin particularly focuses on cardiovascular and haemodynamic therapies. The company reinforces partnerships with governments, working relentlessly to develop safe and effective solutions of the highest quality that meet the specific needs of the medical community, patients and healthcare systems. The Sorin Group showcases these standards through their previously released OVATIO DR, the smallest implantable defibrillator on the market. This device is the size of a credit card, but is just as powerful as any other defibrillator used today.

Sorin's OVATIO was launched in 2006, equipped with SafeR technology.

As if OVATIO wasn't impressive enough, the company is preparing a United States launch of REPLY DR, the world's smallest pacemaker. This tiny device is slightly larger than a quarter, measuring in at 8cm3. Andre-Michel Ballester, President, Sorin CRM says that it's important to note that while this device stands out because of its size, it also has a nine year longevity. REPLY features Sorin's SafeR, which allows the pacemaker to adapt to the patient's natural rhythm. This innovation is intended to limit unnecessary pacing of the right ventricle that may in the long term lead to the development of heart failure or atrial fibrillation. REPLY's small size plays a key role in post-operation follow ups, making them very minimally invasive. "Both the electronic design and the micro-processor give REPLY maximum function and minimum surface size," says Catherine Picard, Vice President, Research and Development, Sorin CRM.